
The European Society of Cardiology released new guidelines at the 2026 Congress to manage the intersection of cardiovascular disease and chronic kidney disease, which affects 100 million Europeans.
The 'STAMP on CKD' strategy mandates screening all cardiovascular patients for kidney issues using blood and urine tests to identify risks earlier in the disease progression.
The guidelines recommend early intervention with RAS inhibitors, SGLT2 inhibitors, and statins to slow kidney decline and reduce cardiovascular complications in high-risk patients.